Toronto Stock Exchange Symbol: MS
EDMONTON, Feb. 8 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS),
a leading developer in the treatment of multiple sclerosis (MS), today
announced that Mr. Kevin Giese, President and CEO, will present at the BIO
CEO & Investor Conference 2008 in New York.
WHEN: Tuesday February 12th at 11:45 am (Eastern Time)
WHERE: Waldorf Astoria Hotel, New York
About BIO CEO & Investor Conference
The objective of the conference is to bring together institutional investors, industry analysts, and senior biotechnology executives in a neutral and collaborative forum to examine investment opportunities and issues affecting the industry. For more information visit: http://ceo.bio.org/opencms/ceo/2008/index.jsp
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking statements, which
reflect the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved